IM Cannabis Corp Dossier - Source-backed chat

IM Cannabis Corp

IMCCNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.75

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.17Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.3M

Enterprise Value $13.5M

Shares Outstanding 603.9K diluted

Moat Rating None

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

IM Cannabis Corp. (IMCC) continues to face severe liquidity constraints, persistent net losses, and substantial doubt regarding its ability to continue as a going concern. While the company is executing a strategic pivot—including a non-binding letter of intent to divest its European activities to reduce debt by CAD$10.5 million and focus on its core Israeli medical cannabis market—it remains highly dependent on dilutive convertible note financings to sustain operations. The combination of ongoing operational losses, high regulatory compliance costs, and listing compliance risks on the Nasdaq Capital Market supports a cautious outlook.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0630%

The bear case is triggered if the sale of European activities falls through, leaving the company with elevated debt and high operational cash burn. Continued failure to meet Nasdaq's minimum bid price requirement could lead to delisting, severely limiting access to capital markets. Under this scenario, the company's going concern risk materializes, potentially forcing a restructuring or insolvency event due to its massive accumulated deficit.

Base CaseCentral scenario

$0.2350%

The base case assumes IM Cannabis continues to navigate a highly fragmented and competitive medical cannabis landscape in Israel with tight working capital. The company will likely remain reliant on incremental private placements and convertible note financings to bridge liquidity gaps. While cost optimization efforts will continue to narrow operating losses, top-line growth is expected to remain constrained, and the stock will face persistent overhead pressure from potential dilution related to convertible note conversions.

Bull CaseUpside scenario

$0.4920%

The bull case relies on the successful and rapid closing of the European asset sale to Slil.com Holding Ltd., which would immediately reduce debt by CAD$10.5 million and streamline the company's focus. Additionally, a stabilization of the Israeli medical cannabis market, combined with aggressive cost-cutting measures (such as the 22% year-over-year reduction in G&A expenses achieved in Q1 2026), could pave the path toward positive operating cash flow and sustainable profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

Significant debt reduction potential of CAD$10.5 million through the proposed sale of European activities.
Demonstrated progress in cost control, highlighted by a 22% year-over-year reduction in general and administrative expenses in Q1 2026.
Established brand presence and distribution infrastructure in the Israeli medical cannabis market.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern due to persistent operating losses and a large accumulated deficit.
High liquidity risk and heavy reliance on dilutive convertible note financings to fund ongoing operations.
Risk of delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.

Thesis Invalidation Triggers

Termination or failure to close the transaction to sell European activities to Slil.com Holding Ltd.
Receipt of a formal delisting notice from Nasdaq.
Inability to secure further debt or equity financing to meet short-term working capital obligations.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.